Recovering scientist turned early stage VC A biotech optimist fighting gravity

Recapturing Our Resilience
February 16, 2022

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving.  It supports our audacity, ability to tune

Leave a comment

Heads Up And Eyes Wide Open
February 7, 2022

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using

Leave a comment

A Tale of Two Biotech Programs
January 24, 2022

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. From the first time I heard the story of the American chestnut, I was fascinated. It is a story with threads from history, ecology,

Leave a comment

How Early Is Too Early To Establish A Commercial Function In Biotech?
January 6, 2022

By Sush Patel, CCO of Replimune as part of the From The Trenches feature of LifeSciVC. After close to 20 years at Genentech (GNE) shaping and directing marketing and commercialization efforts for novel oncology therapies, I finally took the plunge

Leave a comment

Hitting The Spot
November 29, 2021

By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion

Leave a comment

Getting Public Is Easy, Being Public Is Hard
November 18, 2021

We’ve now entered the 46th straight quarter of biotech IPO activity. New equity issuance for biotech in 2021 has broken records for the amount of capital raised, topping even the strong years of 2020 and 2014. Although the open and

Leave a comment

State of the Industry: 2021 Year In Review
November 16, 2021

We just held our first-ever, and hopefully only, virtual Atlas Venture Annual Meeting for our investors. Although science is winning in this pandemic, we’re clearly not back to normal yet so felt it prudent to shift to a virtual format.

Leave a comment

Understanding The Business Model Of Gene Therapy Companies – Peeling The Onion Back To Understand Why Time Matters
November 4, 2021

By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can

Leave a comment

Spreading The Word: Using Different Mediums To Get The Message Out To Your Team
November 1, 2021

By Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Recently, Spero announced the filing of its first ever New Drug Application, for our medicine tebipenem Hbr.  Interestingly, as we approached

Leave a comment

Empowering Therapeutic Advances With Early Patient Engagement
October 7, 2021

By Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC One morning in early June I was reading my LinkedIn feed and saw something that caught my eye – a university was establishing

Leave a comment

Model Behavior
September 29, 2021

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC The COVID-19 pandemic has upended life as we know it. Given so much uncertainty, it is a normal human impulse to want some

Leave a comment

In the Shadows
August 23, 2021

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. I recently stepped down after a six-year stint as Chairman of uniQure (NASDAQ: QURE). In the process of interviewing potential successors, one candidate observed

Leave a comment